A Maintenance Study Evaluating the Long Term Safety of XL999 Administered Intravenously to Subjects With Advanced Malignancies Previously Enrolled in Other XL999 Studies.
Latest Information Update: 29 Sep 2010
Price :
$35 *
At a glance
- Drugs XL 999 (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 23 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2009 New trial record